Flu vaccine used as a Stand-In for infection in new study

NCT ID NCT04164212

Completed Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study gave healthy adults a nasal flu vaccine to safely mimic a mild flu infection. Researchers then measured virus levels and immune responses in nasal samples. A small group also had lung function tests. The goal was to create a reliable model for studying flu without causing severe illness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flumist Quadrivalent Nasal Spray (live attenuated influenza vaccine)
What this could lead to: If successful, this model could help researchers study flu infections and immune responses more easily, potentially speeding up development of new treatments or vaccines.
What could go wrong: This is a small, early-stage model study, not a treatment trial. The vaccine may not fully mimic natural infection, and results may not apply to real-world flu or other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Locations

UAB Lung Health Center

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.